Polygamain, a new microtubule depolymerizing agent that occupies a unique pharmacophore in the colchicine site

Molecular Pharmacology

Volumn 81, Issue 3, 2012, Pages 431-439

  Hartley, R M ^a   Peng, J ^a,c   Fest, G A ^a   Dakshanamurthy, S ^d   Frantz, D E ^c,e   Brown, M L ^d   Mooberry, Susan L ^a,b,c  

^a University of Texas Health Science Center   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c University of Texas Health Science Center at San Antonio   (United States)

^d GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BETA TUBULIN; COLCHICINE; GLYCOPROTEIN P; LIGNAN; PLANT EXTRACT; PODOPHYLLOTOXIN; POLYGAMAIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BINDING SITE; CANCER CELL CULTURE; CELL CYCLE; DRUG RESISTANCE; HUMAN; HUMAN CELL; MICROTUBULE; PHARMACOPHORE; PRIORITY JOURNAL;

BENZOFURANS; CELL CYCLE; CELL LINE; COLCHICINE; DIOXOLES; FLUORESCENT ANTIBODY TECHNIQUE, INDIRECT; HUMANS; INHIBITORY CONCENTRATION 50; MAGNETIC RESONANCE SPECTROSCOPY; MICROTUBULES; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION;

EID: 84863401577     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.111.075838     Document Type: Article

References (48)

1. Banerjee A and Ludueña RF (1992) Kinetics of colchicine binding to purified betatubulin isotypes from bovine brain. J Biol Chem 267:13335-13339.
2. Bayly CI, Cieplak P, Cornell WD, and Kollman PA (1993) A well-behaved electrostatic potential based method using charge restraints for deriving atomic charges-the RESP model. J Phys Chem 97:10269-10280.
3. Bhattacharyya B and Wolff J (1974) Promotion of fluorescence upon binding of colchicine to tubulin. Proc Natl Acad Sci USA 71:2627-2631.
4. Blagosklonny MV, Darzynkiewicz Z, Halicka HD, Pozarowski P, Demidenko ZN, Barry JJ, Kamath KR, and Herrmann RA (2004) Paclitaxel induces primary and postmitotic G1 arrest in human arterial smooth muscle cells. Cell Cycle 3:1050-1056. (Pubitemid 40268664)
5. Boyd MR and Paull KD (1995) Some practical considerations and applications of the national cancer institute in vitro anticancer drug discovery screen. Drug Dev Res 34:91-109.
6. Casanovas J, Namba AM, da Silva R, and Alemán C (2005) DFT-GIAO study of aryltetralin lignan lactones: conformational analyses and chemical shifts calculations. Bioorg Chem 33:484-492. (Pubitemid 41674461)
7. Cortese F, Bhattacharyya B, and Wolff J (1977) Podophyllotoxin as a probe for the colchicine binding site of tubulin. J Biol Chem 252:1134-1140. (Pubitemid 8071267)
8. Das L, Gupta S, Dasgupta D, Poddar A, Janik ME, and Bhattacharyya B (2009) Binding of indanocine to the colchicine site on tubulin promotes fluorescence, and its binding parameters resemble those of the colchicine analogue AC. Biochemistry 48:1628-1635.
9. Dumontet C and Jordan MA (2010) Microtubule-binding agents: a dynamic field of cancer therapeutics. Nat Rev Drug Discov 9:790-803.
10. Dumontet C, Jordan MA, and Lee FF (2009) Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 8:17-25.
11. Eigsti OJ and Dustin P (1955) Colchicine-in Agriculture, Medicine, Biology, and Chemistry, Iowa State College Press, Ames, IA.
12. Galmarini CM, Treilleux I, Cardoso F, Bernard-Marty C, Durbecq V, Gancberg D, Bissery MC, Paesmans M, Larsimont D, Piccart MJ, et al. (2008) Class III betatubulin isotype predicts response in advanced breast cancer patients randomly treated either with single-agent doxorubicin or docetaxel. Clin Cancer Res 14: 4511-4516.
13. Gangjee A, Zhao Y, Hamel E, Westbrook C, and Mooberry SL (2011) Synthesis and biological activities of (R)- and (S)-N-(4-methoxyphenyl)-N,2,6-trimethyl- 6,7- dihydro-5H-cyclopenta[d]pyrimidin-4-aminium chloride as potent cytotoxic antitubulin agents. J Med Chem 54:6151-6155.
14. Gottesman MM, Fojo T, and Bates SE (2002) Multidrug resistance in cancer: role of ATP-dependent transporters. Nat Rev Cancer 2:48-58. (Pubitemid 37328807)
15. Hokanson GC (1979) Lignans of polygala-polygama (polygalaceae)- deoxypodophyllotoxin and 3 new lignan lactones. J Nat Prod 42:378-384.
16. Huang HC, Shi J, Orth JD, and Mitchison TJ (2009) Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 16:347-358.
17. James J, Murry DJ, Treston AM, Storniolo AM, Sledge GW, Sidor C, and Miller KD (2007) Phase I safety, pharmacokinetic and pharmacodynamic studies of 2-methoxyestradiol alone or in combination with docetaxel in patients with locally recurrent or metastatic breast cancer. Invest New Drugs 25:41-48. (Pubitemid 44657641)
18. Kavallaris M (2010) Microtubules and resistance to tubulin-binding agents. Nat Rev Cancer 10:194-204.
19. Krishan A (1975) Rapid flow cytofluorometric analysis of mammalian cell cycle by propidium iodide staining. J Cell Biol 66:188-193.
20. Lee L, Robb LM, Lee M, Davis R, Mackay H, Chavda S, Babu B, O'Brien EL, Risinger AL, Mooberry SL, et al. (2010) Design, synthesis, and biological evaluations of 2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoline analogs of combretastatin-A4. J Med Chem 53:325-334.
21. Ludueña RF (1998) Multiple forms of tubulin: different gene products and covalent modifications. Int Rev Cytol 178:207-275.
22. Ludueña RF and Banerjee A (2008) The isotypes of tubulin, in The Role of Microtubule in Cell Biology, Neurobiology, and Oncology (Fojo T ed), Humana Press, Totowa, NJ.
23. Mooberry SL, Tien G, Hernandez AH, Plubrukarn A, and Davidson BS (1999) Laulimalide and isolaulimalide, new paclitaxel-like microtubule-stabilizing agents. Cancer Res 59:653-660. (Pubitemid 29076064)
24. Nguyen TL, McGrath C, Hermone AR, Burnett JC, Zaharevitz DW, Day BW, Wipf P, Hamel E, and Gussio R (2005) A common pharmacophore for a diverse set of colchicine site inhibitors using a structure-based approach. J Med Chem 48:6107-6116. (Pubitemid 41324618)
25. Noble RL, Beer CT, and Cutts JH (1958) Role of chance observations in chemotherapy: Vinca rosea. Ann NY Acad Sci 76:882-894.
26. Panda D, Miller HP, Banerjee A, Ludueña RF, and Wilson L (1994) Microtubule dynamics in vitro are regulated by the tubulin isotype composition. Proc Natl Acad Sci USA 91:11358-11362. (Pubitemid 24356343)
27. Penson RT, Oliva E, Skates SJ, Glyptis T, Fuller AF Jr, Goodman A, and Seiden MV (2004) Expression of multidrug resistance-1 protein inversely correlates with paclitaxel response and survival in ovarian cancer patients: a study in serial samples. Gynecol Oncol 93:98-106. (Pubitemid 38429555)
28. Pettit GR, Cragg GM, and Singh SB (1987) Antineoplastic agents, 122. Constituents of Combretum caffrum. J Nat Prod 50:386-391. (Pubitemid 17134088)
29. Pettit GR, Temple C Jr, Narayanan VL, Varma R, Simpson MJ, Boyd MR, Rener GA, and Bansal N (1995) Antineoplastic agents 322. Synthesis of combretastatin A-4 prodrugs. Anticancer Drug Des 10:299-309.
30. Podwyssotzki V (1880) Pharmakologische Studien uber Podophyllum peltatum. Arbeiten aus dem pharmakologischem Institut der Universitat Dorpat 16:29-52.
31. Rao PN, Cessac JW, Tinley TL, and Mooberry SL (2002) Synthesis and antimitotic activity of novel 2-methoxyestradiol analogs. Steroids 67:1079-1089. (Pubitemid 35341726)
32. Ravelli RB, Gigant B, Curmi PA, Jourdain I, Lachkar S, Sobel A, and Knossow M (2004) Insight into tubulin regulation from a complex with colchicine and a stathmin-like domain. Nature 428:198-202. (Pubitemid 38374318)
33. Risinger AL, Jackson EM, Polin LA, Helms GL, LeBoeuf DA, Joe PA, Hopper-Borge E, Ludueña RF, Kruh GD, and Mooberry SL (2008) The taccalonolides: microtubule stabilizers that circumvent clinically relevant taxane resistance mechanisms. Cancer Res 68:8881-8888.
34. Risinger AL and Mooberry SL (2011) Cellular studies reveal mechanistic differences between taccalonolide A and paclitaxel. Cell Cycle 10:2162-2171.
35. Risinger AL, Westbrook CD, Encinas A, Mülbaier M, Schultes CM, Wawro S, Lewis JD, Janssen B, Giles FJ, and Mooberry SL (2011) ELR510444, a novel microtubule disruptor with multiple mechanisms of action. J Pharmacol Exp Ther 336:652-660.
36. Sève P, Reiman T, and Dumontet C (2010) The role of betaIII tubulin in predicting chemoresistance in non-small cell lung cancer. Lung Cancer 67:136-143.
37. Sheriha GM, Abouamer K, Elshtaiwi BZ, Ashour AS, Abed FA, and Alhallao HH (1987) Quinoline alkaloids and cytotoxic lignans from haplophyllum- tuberculatum. Phytochemistry 26:3339-3341.
38. Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S, and Boyd MR (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J Natl Cancer Inst 82:1107-1112. (Pubitemid 20213250)
39. Smith CD, Zhang X, Mooberry SL, Patterson GM, and Moore RE (1994) Cryptophycin: a new antimicrotubule agent active against drug-resistant cells. Cancer Res 54:3779-3784. (Pubitemid 24241196)
40. Tinley TL, Leal RM, Randall-Hlubek DA, Cessac JW, Wilkens LR, Rao PN, and Mooberry SL (2003a) Novel 2-methoxyestradiol analogues with antitumor activity. Cancer Res 63:1538-1549. (Pubitemid 36373641)
41. Tinley TL, Randall-Hlubek DA, Leal RM, Jackson EM, Cessac JW, Quada JC Jr, Hemscheidt TK, and Mooberry SL (2003b) Taccalonolides E and A: plant-derived steroids with microtubule-stabilizing activity. Cancer Res 63:3211-3220. (Pubitemid 36735874)
42. Torin Huzil J, Ludueña RF, and Tuszynski J (2006) Comparative modelling of human β tubulin isotypes and implications for drug binding. Nanotechnology 17:S90-S100. (Pubitemid 43190484)
43. Towle MJ, Salvato KA, Wels BF, Aalfs KK, Zheng W, Seletsky BM, Zhu X, Lewis BM, Kishi Y, Yu MJ, et al. (2011) Eribulin induces irreversible mitotic blockade: implications of cell-based pharmacodynamics for in vivo efficacy under intermittent dosing conditions. Cancer Res 71:496-505.
44. Wang J, Wolf RM, Caldwell JW, Kollman PA, and Case DA (2004) Development and testing of a general amber force field. J Comput Chem 25:1157-1174.
45. Wani MC, Taylor HL, Wall ME, Coggon P, and McPhail AT (1971) Plant antitumor agents. VI. The isolation and structure of Taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J Am Chem Soc 93:2325-2327.
46. Wozniak KM, Nomoto K, Lapidus RG, Wu Y, Carozzi V, Cavaletti G, Hayakawa K, Hosokawa S, Towle MJ, Littlefield BA, et al. (2011) Comparison of neuropathyinducing effects of eribulin mesylate, paclitaxel, and ixabepilone in mice. Cancer Res 71:3952-3962.
47. Xu H, Lv M, and Tian X (2009) A review on hemisynthesis, biosynthesis, biological activities, mode of action, and structure-activity relationship of podophyllotoxins: 2003-2007. Curr Med Chem 16:327-349.
48. Yeh JJ, Hsu WH, Wang JJ, Ho ST, and Kao A (2003) Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression. Respiration 70:32-35. (Pubitemid 36216644)